Pre-procedural dual antiplatelet therapy in patients undergoing transcatheter aortic valve implantation increases risk of bleeding
Conclusions
The current study demonstrated that DAPT before TF-TAVI increased the risk of bleeding compared with single or no antiplatelet therapy. Lower intensity antiplatelet therapy was not associated with thrombotic events. In modern practice, it might be reasonable to perform TAVI using single or no pre-procedural antiplatelet therapy with an expectation of no increase of adverse events.
Trial registration number
UMIN-ID; 000020423; Results.
Source: Heart - Category: Cardiology Authors: Hioki, H., Watanabe, Y., Kozuma, K., Nara, Y., Kawashima, H., Kataoka, A., Yamamoto, M., Takagi, K., Araki, M., Tada, N., Shirai, S., Yamanaka, F., Hayashida, K., And on behalf of OCEAN-TAVI investigators Tags: Valvular heart disease Source Type: research
More News: Bleeding | Cardiology | Heart | Heart Attack | Heart Disease | Stroke | Study | Thrombosis